

P1397 CHRONICALLY REDUCED LEVELS OF THROMBOPOIETIN IMPAIR HEMATOPOIETIC STEM CELL FUNCTION AND MEGAKARYOCYTE BONE MARROW NICHE

Topic: 23. Hematopoiesis, stem cells and microenvironment

Annamaria Aprile¹, Mariangela Storto¹, Alessandro Malara^{2, 3}, Alessandro Gulino⁴, Laura Raggi¹, Silvia Sighinolfi^{1, 5}, Stefano Beretta¹, Ivan Merelli^{1, 6}, Sarah Markt⁷, Maurizio Ponzoni^{8, 9}, Claudio Tripodo⁴, Alessandra Balduini^{2, 3}, Giuliana Ferrari^{1, 5}

¹ San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy; ² Department of Molecular Medicine, University of Pavia, Pavia, Italy; ³ Laboratory of Biochemistry, Biotechnology and Advanced Diagnostics, IRCCS San Matteo Foundation, Pavia, Italy; ⁴ Tumor Immunology Unit, Human Pathology Section, Department of Health Sciences, University of Palermo, Palermo, Italy; ⁵ Vita-Salute San Raffaele University, Milan, Italy; ⁶ Institute for Biomedical Technologies, National Research Council, Segrate, Italy; ⁷ Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; ⁸ Pathology Unit; ⁹ Unit of Lymphoid Malignancies, IRCCS San Raffaele Scientific Institute, Milan, Italy

Background: In the last decade many studies unraveled the regulation of the bone marrow (BM) niche and hematopoietic stem cells (HSC) by using transgenic knock-out or reporter mice, in steady state or upon acute stimulation. However, HSC-niche interactions are still underexplored in disease condition associated to chronic stress. Beta-thalassemia (BT) is a severe congenital anemia with ineffective erythropoiesis and multi-organ secondary complications and may represent an ideal model to study HSC in a chronically altered BM microenvironment. We recently demonstrated an impaired function of HSC due to the defective crosstalk with stromal BM niche in BT mice (Aprile *et al.*, *Blood* 2020). In addition to the BM stroma, we found altered levels of multiple local and systemic factors, including reduction of systemic thrombopoietin (TPO).

Aims: Further investigation is pivotal to define the role of chronically reduced stimulation of TPO signaling on HSC and BM microenvironment.

Methods: Gene expression profiling of HSC, megakaryocytes (Mk) and spleen macrophages from *Hbb^{th3/+} (th3)* BT mice was assessed by RNAseq analysis. Flow cytometry characterization, *in vitro* Mk maturation, histological analysis on the BM of BT mice and patients, *in vivo* platelet (Plt) biogenesis, half-life and phagocytosis were performed. *In vivo* stimulation of TPO was evaluated.

Results:

Since TPO is a key regulator of both HSC and Mk, we investigated the dual role of TPO defect in the disease model of BT. RNAseq profiling revealed a downregulation of TPO signaling and target stemness genes in *th3* HSC, including *Cdkn1a*, *Hoxa9* and *Hoxb4*, negatively affecting HSC function. The decreased TPO causes a reduced commitment of HSC towards the Mk lineage, with under-expression of Mk-biased genes and lower frequency of CD41⁺CD9^{high} HSC. *In vivo* stimulation of TPO axis in *th3* mice restored the pool of quiescent HSC, thus demonstrating the contribution of defective TPO signaling in altering BT HSC.

Consistently, histopathological analyses of *th3* mice showed dysmegakaryopoiesis and this defect was confirmed in BM sections from BT patients. The decreased maturation of *th3* Mk, with loss of the mature polyploid profile, correlated with a reduced *in vivo* Plt biogenesis and impaired *in vitro* differentiation of *th3* Mk. Sorted BT Mk showed the downregulation of niche factors, as *Pf4*, *Cxcl12*, *TnC*, relevant for HSC maintenance and reduced expression of extracellular matrix molecules, contributing to the impaired HSC-niche crosstalk.

We explored the origin of TPO defect: TPO levels fluctuate in response to Plt number and its reduced production by hepatocytes in *th3* mice is associated to the increased count of Plt. A negative correlation between Plt and TPO was

Copyright Information: (Online) ISSN: 2572-9241

© 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2022;6:(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.

confirmed in BT patients. Consistently, acute Plt depletion in *th3* animals is sufficient to restore normal TPO levels, thus excluding an intrinsic defect. *In vivo* labeling demonstrated a higher half-life of BT Plt, which accumulate in the circulation. Phagocytosis assays proved a reduced Plt clearance by *th3* spleen macrophages, whose activity is impaired by iron overload and increased erythrophagocytosis associated to the disease.

Summary/Conclusion: Our results unraveled the dual role of TPO on HSC and Mk BM niche in a disease condition of chronically reduced TPO stimulation. This research elucidates the multiple mechanisms of the BM niche regulation in a model of chronic hematopoietic stress, with a potential relevance in improving HSC transplantation approaches for hematological diseases.

Copyright Information: (Online) ISSN: 2572-9241

© 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2022;6:(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.